Moreover, in another study, using immunohistochemical analysis (IHC) we recently retrospectively demonstrated that stage-II/IIIA patients with lung adenocarcinoma in which the ACTN4 protein is overexpressed got clinical benefit for overall survival from ADJ with cisplatin and vinorelbin. This evidence concerns the gene ACTN4 and lung adenocarcinoma.